As of June 9, 2025, Pfizer Inc (PFE) reports a Gross Margin of 74.33%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Historical Trend of Pfizer Inc's Gross Margin
Over recent years, Pfizer Inc's Gross Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Gross Margin |
|---|---|
| 2024-12-31 | 74.33% |
| 2023-12-31 | 70.13% |
| 2022-12-31 | 66.30% |
| 2021-12-31 | 62.25% |
| 2020-12-31 | 79.82% |
This slight upward trend highlights how Pfizer Inc manages its operational efficiency and pricing power over time.
Comparing Pfizer Inc's Gross Margin to Peers
To better understand Pfizer Inc's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| Pfizer Inc (PFE) | 74.33% |
| NGM Biopharmaceuticals Inc (NGM) | 7775.20% |
| Corcept Therapeutics Inc (CORT) | 98.39% |
| Innoviva Inc (INVA) | 89.80% |
| Supernus Pharmaceuticals Inc (SUPN) | 89.57% |
| Jazz Pharmaceuticals PLC (JAZZ) | 89.05% |
Compared to its competitors, Pfizer Inc's Gross Margin is about average compared to peers, indicating industry-standard operational efficiency.